Home

HyTest Summa Equity

Over 640+Bleakhall Motors deals redeemed. Get Exclusive Deals With Groupon. Limited Time Offer Summa Equity will become majority shareholder of the Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry. The growing company operates in a global market where growth is driven by an aging population, innovation and increasing investments in medical care Summa Equity has agreed to sell HyTest to Mindray for €545 million Summa Equity has signed a definitive agreement to sell HyTest, a leading developer and producer of high-performance antibodies and antigens to Mindray, a leading global medical technology company for total consideration of approximately €545 million

May 18, 2021 | News | 0 comments. Summa Equity is to sell HyTest, a developer and producer of antibodies and antigens, to Mindray, a global medical technology company, for total consideration of approximately $666m. Since Summa Equity's acquisition of HyTest in 2018, the company has continued to develop its industry leading antibodies and antigens. Riskkapitalbolaget Summa Equity säljer Hytest till medicinteknikbolaget Mindray för 545 miljoner euro, motsvarande 5,5 miljarder kronor. Det framgår av ett pressmeddelande. Hytest, som utvecklar antikroppar och antigener, har i dag en produktportfölj som täcker över 20 sjukdomsgrupper Summa Equity acquires Finnish antibody manufacturer HyTest. Summa Equity will become majority shareholder of the Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry. The growing company operates in a global market where growth is driven by an aging population, innovation and increasing investments in medical care Summa Equity AB is exploring a sale of Finland's HyTest Ltd. , a manufacturer of antibodies and antigens used in tests for illnesses including Covid-19, people with knowledge of the matter said

Summa Equity säljer Hytest för 545 miljoner euro. Riskkapitalbolaget Summa Equity säljer Hytest till medicinteknikbolaget Mindray för 545 miljoner euro, motsvarande 5,5 miljarder kronor. Hytest, som utvecklar antikroppar och antigener, har i dag en produktportfölj som täcker över 20 sjukdomsgrupper Riskkapitalbolaget Summa Equity har tecknat ett slutgiltigt avtal om att sälja HyTest till medicinteknikbolaget Mindray för en total ersättning på cirka 545 miljoner euro. Detta framgår av ett pressmeddelande. Tre år i portföljen. Summa Equity förvärvade HyTest 2018 Summa Equity has agreed to sell HyTest to Mindray for €545 million Summa Equity has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company. Exi EQT Credit provides financing for Summa Equity's investment in HyTest. EQT Credit, through its Mid-Market Credit investment strategy, today announced that is has provided a senior secured financing solution to support Summa Equity's investment in HyTest. Founded in 1994 as a spinoff from a project within Turku University, HyTest is a high-quality,.

Summa Equity blir majoritetsägare i det finska bolaget HyTest, tillverkare av antikroppar och antigener som möjliggör medicinsk diagnostik. Det växande bolaget är verksamt på en global marknad vars tillväxt drivs av en åldrande befolkning, innovation och ökande investeringar i vård och hälsa Summa Equity, a leading Nordic private equity investor, has acquired majority shareholding of the Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry. HyTest was founded in 1994 by a group of Russian scientists who are still members of senior management

Since Summa Equity's acquisition of HyTest in 2018, the company has continued to develop its industry leading antibodies and antigens product portfolio, maintaining and growing market leading positions in several key segments, including cardiac markers, inflammation and infectious diseases Summa Equity, ett ledande nordiskt investmentbolag, har förvärvat majoriteten av det finska företaget HyTests aktieinnehav. HyTest tillverkar antikroppar och antigener för diagnostikindustrin. Företaget grundades 1994 av en grupp ryska vetenskapsmän, som fortfarande har ledande befattningar i företaget Swedish private equity firm Summa Equity has agreed to sell HyTest, a developer and producer of antibodies and antigens, to trade buyer Mindray for €545m. , Exits, Nordics, Healthcare, Finland, Summa Equity, Nordic healthcare, Trade sal Summa Equity has agreed to sell HyTest to Mindray for 545 million euros. William Blair has been acting as financial advisor to HyTest on the deal while Avance was legal advisor

HyTest's current majority owner, Summa Equity, has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company. HyTest has been partnering with Mindray already for over ten years EQT Credit, through its Mid-Market Credit investment strategy, today announced that is has provided a senior secured financing solution to support Summa Equity's investment in HyTest. Founded in 1994 as a spinoff from a project within Turku University, HyTest is a high-quality, global antibody and antigens manufacturer and supplier, primarily targeting in vitro diagnostics (IVD) OEMs and. BDA Partners is pleased to announce HyTest Invest Oy (HyTest), a portfolio company of Summa Equity, advised by William Blair in conjunction with BDA Partners, has agreed to be acquired by Mindray (Shenzhen Stock Exchange Ticker: 300760) for €545 million in total consideration. The transaction was signed on May 16, 2021 and is expected to close in. MOT and Wheel Alignment Check. Save up to 0% with your MOT and Wheel Alignment Check Dea

Avance advises Summa Equity in the sale of HyTest, a leading developer and producer of high-performance antibodies and antigens, to Mindray, a leading global medical technology company, for total consideration of approximately EUR 545 million. Finland-based HyTest was founded in 1994 and has currently around 130 employees Summa Equity to sell HyTest to Mindray for EUR545m Submitted 17/05/2021 - 1:33pm Summa Equity is to sell HyTest, a developer and producer of antibodies and antigens, to Mindray, a global medical technology company, for total consideration of approximately EUR545 million. Since Summa Equity's acquisition of HyTest in 2018, the company has continued to develop its industry leading antibodies and.

Soothe night time itching - How to stop itchin

Summa Equity will become majority shareholder of Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry. The growing company operates in a global market where growth is driven by an aging population, innovation and increasing investments in medical care. The investment is Summa Equity's first in the Finnish. Summa Equity has acquired Finnish antibody manufacturer HyTest. No financial terms were disclosed. Summa Equity will become majority shareholder of the Finnish company HyTest, producer of antibodies and antigens for the diagnostic industry. The growing company operates in a global market where growth is driven by an aging population, innovation. Summa Equity is to sell HyTest, a developer and producer of antibodies and antigens, to Mindray, a global medical technology company, for total consideration of approximately EUR545 million. - #private-equity #HedgeMave

Bleakhall Motors deals - Save Up to 44% Of

EQT Credit, through its Mid-Market Credit investment strategy, today announced that is has provided a senior secured financing solution to support Summa Equity's investment in HyTest. Founded in 1994 as a spinoff from a project within Turku University, HyTest is a high-quality, global antibody and antigens manufacturer and supplier, primarily targeting in vitro diagnostics (IVD) [ EQT Credit Provides Financing for Summa Equity's Investment in HyTest. PRESS RELEASE PR Newswire . Sep. 7, 2018, 03:19 AM William Blair acted as the exclusive financial advisor to HyTest, a portfolio company of Summa Equity in connection with its pending sale to Mindray (Shenzen Stock Exchange Ticker: 300760) for €545 million in total consideration. The transaction was signed on May 16, 2021 and is expected to close in the second half of 2021. Transaction Highlight

Riskkapitalbolaget Summa Equity säljer Hytest till medicinteknikbolaget Mindray för 545 miljoner euro, motsvarande 5,5 miljarder kronor Nordic buyout firm Summa Equity has acquired Finnish antibody manufacturer HyTest., Buyouts, Nordics, Healthcare, Finland, Summa Equity Summa Equity Summa Equity was founded in 2016 by an experienced group of people that have a long track record from investing in successful companies. Announced Date Sep 6, 2018. Acquisition Type Leveraged Buyout. Acquisition Status Complete. Disposition of Acquired Organization Separate Entity HyTest could fetch as much as $400 million in a sale, the people said, citing strong investor interest in testing due to the pandemic. Deliberations are at an early stage and Summa could decide to keep the business, according to the people. A representative for Summa Equity did not respond to requests for comment

Hytest Sweden AB - Org.nummer: 559083-7000. På Bolagsfakta.se hittar du kontakt-och företagsinformation, nyckeltal, lön till VD & styrelse m.m Myyjänä on norjalainen pääomasijoitusyhtiö Summa Equity, joka hankki enemmistön Hytestistä vuonna 2018. Vuonna 1994 perustettu Hytest valmistaa vasta-aineita ja antigeenejä diagnostiikkateollisuuden raaka-aineiksi, pääasiassa laboratoriotestejä varten. Toissa vuonna yhtiö teki noin 25 miljoonan euron liikevaihdon Summa Equity has agreed to sell HyTest, a developer of antibodies and antigens for diagnostics tests, to medical technology company Mindray for around €545 million. Summa Equity acquired Finland-based HyTest in 2018 In September 2018, Nordic private equity firm Summa Equity announced the acquisition of a majority stake in HyTest, which is based in Turku, Finland. At the time of the acquisition, the Finnish company employed around 100 employees, with a presence across the globe, including US, Asia and Europe HyTest, a Finnish producer of antibodies and antigens for the diagnostics industry, has a new majority shareholder in Summa Equity. 06.09.2018. Share. HyTest 's customer base includes a large number of companies that sell in vitro diagnostics (IVD) equipment, which use antibodies and antigens to diagnose and follow disease development

Riskkapitalbolaget Summa Equity säljer Hytest till medicinteknikbolaget Mindray för 545 miljoner euro, motsvarande 5,5 miljarder kronor. Det framgår av ett pressmeddelande. ANNONS. Hytest, som utvecklar antikroppar och antigener, har i dag en produktportfölj som täcker över 20 sjukdomsgrupper. Bolaget är. Avance advises Summa Equity, a Nordic private equity sponsor in its majority investment in Hytest, a globally recognized leader in the space of manufacturing of antibodies and antigens. The transaction is Summa Equity's first in Finland since it was founded in 2016 HyTest Has Agreed to Be Acquired by Mindray. Tuesday, May 18, 2021. - /. William Blair acted as the exclusive financial advisor to HyTest, a portfolio company of Summa Equity in connection with its pending sale to Mindray (Shenzen Stock Exchange Ticker: 300760) for €545 million in total consideration. The transaction was signed on May 16. Big news from #teamhytest: going forward, we will be a part of Mindray. ⬇ Our current majority owner, Summa Equity, has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company for total consideration of approximately €545 million.HyTest has been partnering with Mindray already for over a decade, during which we have established friendship and.

HyTest - Summa Equit

  1. Our current majority owner, Summa Equity, has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company. We are delighted to partner with Mindray as we look forward to the future in delivering the best products and service to our global customer base
  2. Summa Equity AB 559064-1444 (Stockholm) Översikt Telefonnummer Adresser Styrelse och koncern Verklig huvudman Nyckeltal Kreditupplysning Skicka Hytest Invest Oy eGain Group AB 2 anställda Omsättning 12 723 tkr Resultat -17 828 tkr eGain International AB 15 anställda Omsättning 35 545 tk
  3. Summa Equity AB (559064-1444). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar
  4. HyTest could fetch as much as $400 million in a sale, the people said, citing strong investor interest in testing due to the pandemic. Deliberations are at an early stage and Summa could decide to keep the business, according to the people. A representative for Summa Equity did not respond to requests for comment. Founded in 1994, HyTest.
  5. HyTest's original holding fund, Summa Equity, will release an announcement to summarize from the fundamentals of the transaction: IVD is the growth engine of the global medical device market, and the growth rate of China's IVD market leads the world
  6. Summa Equity Holding AB (559117-1219). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar
  7. Summa Equity AB Summa Equity AB Overview. Date Founded. 2016. Headquarters. David Bagares gata 3,Stockholm 111 38. Type of Company. Private. Industries. Private Equity Summa Equity buys Finnish antibody manufacturer HyTest RelSci September 1, 2018 Anna Ryott is.

På samma adress finns även följande företag registrerade, Summa Equity Fund I (No. 1) AB, Summa Equity Fund I (No. 2) AB, Summa Equity Fund I (No. 3) AB, Hytest Sweden AB, Vålåuggen Invest AB, Vålåuggen Förvaltning AB, Co-Investment (No. 1) AB och Co-Investment (No. 2) AB med flera. Läs mer om intressant företagsstatistik i Stockhol HyTest Has Agreed to Be Acquired by Mindray. William Blair acted as the exclusive financial advisor to HyTest, a portfolio company of Summa Equity in connection with its pending sale to Mindray (Shenzen Stock Exchange Ticker: 300760) for €545 million in total consideration Hytest Invest Oy eGain Group AB 2 anställda Omsättning 12 723 tkr Resultat -17 828 tkr eGain International AB 15 anställda Omsättning 35 545 tkr Summa Equity Fund II (No. 2) AB Omsättning 0 tkr Resultat 55 601 tkr Summa Equity Fund II (No. 3) AB Omsättning 0 tkr Resultat -4 794 tk HyTest Oy manufactures biological products. It operates as producer of monoclonal antibodies and antigens for the diagnostic industry. The company was founded in 1994 and is headquartered in Turku, Finland

Salem has served as a Principle of Summa Equity AB since March 2020. Since its inception in January 2019, Mr. Salem has served as the co-founder and managing partner of Eureka Life Science LLC, which provides business strategy and commercialization support for innovative companies across the life sciences and diagnostics markets (Bloomberg) -- Nordic private equity firm Summa Equity AB is exploring a sale of Finland's HyTest Ltd., a manufacturer of antibodies and antigens used in tests for illnesses including Covid-19. HyTest was acquired by Summa Equity on September 6, 2018. Life Science Company. Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2018. The largest life science acquisition in 2018 was Shire - which was acquired by Takeda Pharmaceutical for $67.7B /PRNewswire/ -- EQT Credit, through its Mid-Market Credit investment strategy, today announced that is has provided a senior secured financing solution to.. Summa Equity Partners has made its first investment in the Finnish market by agreeing to become a majority shareholder in antibodies and antigens producer HyTest

Summa Equity has agreed to sell HyTest to Mindray for €545

  1. STOCKHOLM, Sept. 7, 2018 /PRNewswire/ -- EQT Credit, through its Mid-Market Credit investment strategy, today announced that is has provided a senior secured financing solution to support Summa
  2. Summa Equity säljer Hytest för 545 miljoner euro → Realtid 09:22 Riskkapitalbolaget Summa Equity säljer Hytest till medicinteknikbolaget Mindray för 545 miljoner euro, motsvarande 5,5 miljarder kronor..
  3. List of Summa Equity 's 10 Acquisitions, including Sengenics and Olink. Save Search . Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved . Acquirer Name
HyTest - EQT

Summa seeks to invest in and develop companies that provide these solutions. Through their products or services, these companies aim to reduce climate change, mitigate resource scarcity, improve education, health and well-being or provide sustainable energy sources. About Summa Company profile page for Summa Equity AB including stock price, company news, press releases, executives, board members, and contact informatio Summa Equity is to sell HyTest, a developer and producer of antibodies and antigens, to Mindray, a global medical technology company, for total consideration of approximately EUR545 million. 17/05/2021. Story. NV5 acquires PES Environmental NV5 acquires PES Environmental Summa Equity to sell HyTest to Mindray for EUR545m Summa Equity to sell HyTest to Mindray for EUR545m Submitted 17/05/2021 - 1:33pm Summa Equity is to sell HyTest, a developer and producer of antibodies and antigens, to Mindray, a global medical technology company, for total consideration of approximately EUR545 million Cohere Capital Partners (Cohere), a Boston-based private equity firm focused exclusively on middle market growth companies, today announced the successful closing of its debut fund, Cohere Capital Fund I, LP (the Fund) at $200 million. The Fund closed over its target and at its hard cap without the use of a placement agent

Summa Equity Acquires Finnish Antibody - HyTest Ltd

Summa Equity has sealed the exit of high-performance antibodies and antigens developer HyTest to trade buyer Mindray in a €545m deal. The private equity house said HyTest had maintained and grown market leading positions in several key segments since its 2018 buyout , including cardiac markers, inflammation and infectious diseases Summa Equity is to sell HyTest, a developer and producer of antibodies and antigens, $666m, to Mindray, a global medical technology company. Since Gillas av Tommi Unkur Summa Equity | 8,160 followers on LinkedIn. We turn challenges into business opportunities and allow companies to grow, while building a sustainable future. | Summa Equity invests in companies that have leading solutions to global challenges and that create positive Environmental, Social, and Governance (ESG) outcomes for society. We co-create win-win for our investors, our companies, and.

Summa Equity to sell HyTest to Mindray for $666m Private

Summa Equity has sealed the exit of high-performance antibodies and antigens developer HyTest to trade buyer Mindray in a €545m deal. The private equity house said HyTest had maintained and grown market leading positions in several key segments since its 2018 buyout, including cardiac markers, inflammation and infectious diseases HyTest | 1,805 followers on LinkedIn. We manufacture monoclonal antibodies and antigens that are mainly used as key components of laboratory tests. | Together. Today and Tomorrow. With over 20 years of experience HyTest offers innovative solutions for assay development and research applications by providing high-quality immunological reagents in such areas as cardiac markers, infectious. Riskkapitalbolaget Summa Equity säljer Hytest till medicinteknikbolaget Mindray för 545 miljoner euro, motsvarande 5,5 miljarder kronor.. Realtid - 1 timme sedan EQT avyttrar Adapteo-innehavet till Goldman Sachs fond. EQT säljer sin andel i modulbyggnationsspecialisten Adapteo till en premie om 53 procent.

Summa Equity säljer Hytest för 545 miljoner euro Placer

We assisted the shareholders of HyTest Ltd in the sale of the majority shareholding to a private equity fund Summa Equity. Our advice included tax structuring for the sellers and drafting and negotiating the documents relating to the transaction including the sellers' re-investment Riskkapitalbolaget Summa Equity säljer Hytest till medicinteknikbolaget Mindray för 545 miljoner euro, motsvarande 5,5 miljarder kronor.. Realtid - 4 timmar sedan EQT avyttrar Adapteo-innehavet till Goldman Sachs fond. EQT säljer sin andel i modulbyggnationsspecialisten Adapteo till en premie om 53 procent. Acquired by Summa Equity in 2018, HyTest's products span more than 20 disease areas and offer antibodies and antigens for in vitro diagnostic (IVD) tests. These IVD tests are used on more than 300 million people across the globe annually Mindray to acquire HyTest from Summa Equity for $665m. (FS) Mindray, a company that develops, manufactures, and markets medical devices, agreed to acquire HyTest, a manufacturer of scientifically created antibodies, from Summa Equity, a thematic investment companyб for $665m På allabolag.se hittar du företagsinformation om Jenny Maria Keisu. allabolag.se ger alla tillgång till bokslut, befattningshavare, kreditupplysningar, adresser och annan företagsinformation

Summa Equity acquires Finnish antibody manufacturer HyTes

Hytest Sweden AB. Summa Equity Holding AB. Iru Holding AB. Thamani InvestCo AB. Knilo InvestCo AB. Olink Holding AB (publ) Knilo BidCo AB. Knilo ManCo AB. Gramin Holding AB. Tommi Markus Unkuri Jon Aron Olof Heimer 7 företag. Johan Viktor Pietilä Holmner. Nordea-chef döms till två års fängelse för grova insiderbrot

Nordic PE Firm Summa Equity Exploring Sale of Finland's

  1. Summa Equity säljer Hytest för 545 miljoner euro Realtid
  2. Summa Equity säljer Hytest för 545 miljoner euro Dagens
  3. Home - Summa Equit
  4. HyTest - EQ

Summa Equity förvärvar den finska antikropptillverkaren HyTes

  1. Summa Equity acquires shares in HyTest - Mannheimer Swartlin
  2. Summa Equity förvärvar aktier i HyTest - Mannheimer Swartlin
  3. Summa Equity to sell HyTest in €545m trade deal Unquot
Norsk Gjenvinning - Summa EquityJeanette Anttila - Summa Equity

Summa Equity to sell HyTest to Mindray PE Hu

  1. HyTest Ltd
  2. Summa Equity to sell HyTest to Mindray for EUR545m
  3. EQT Credit provides financing for Summa Equity's
  4. Best Deals Near You · Transport · Car Cleanin
Elisabeth Gogstad Aanonsen - Summa EquityKari Ringi - Summa EquityWe - Summa Equity
  • Lie nf lyrics.
  • Index trading vs stock trading.
  • Hierheen 3 letters.
  • FREE coin PancakeSwap.
  • Haldex Halmstad.
  • FinTech Acquisition Corp V website.
  • PostNord öppettider.
  • 22 åring Vetlanda Flashback bild.
  • Fintech Aktie Niederlande.
  • Late Night Berlin Joyn.
  • Money Laundering Regulations 2020 estate agents.
  • KTH medieteknik master.
  • How to get freelancers for startup.
  • Silber Philharmoniker differenzbesteuert.
  • EToro Wallet login.
  • Plockavgift ICA Maxi.
  • Enklare lån Flashback.
  • E mini futures trading strategies.
  • Amazon 401k Fidelity.
  • Etrade Bank Zelle.
  • NIBE växelriktare.
  • Savings calculator Ireland.
  • XRP price.
  • Mercato Locarno COVID.
  • Kinder morgan terminal.
  • Dogecoin price in India in Hindi.
  • Sweco architects.
  • Crypto pump groups.
  • Do you need a Steam card for PayPal.
  • Swiss lakes.
  • IPhone block number not working.
  • Dead cryptocurrency.
  • Bukowskis Malmö öppettider.
  • RAM based crypto mining.
  • Payback period calculator.
  • Balansbudget moms.
  • SWAP Token price.
  • Nyfosa Forum.
  • EOS vs Ethereum 2021.
  • MoneyPool ohne PayPal Konto.
  • Vad betyder relevant på svenska.